EcoDrugPlus

60s Ribosomal Protein L19

Ensembl ID : ENSXMAG00000008471
Gene Symbol: LOC102236045
3 Cross references
333 Possible Orthologues:

60s Ribosomal Protein L22

Ensembl ID : ENSXMAG00000004585
Gene Symbol: LOC102235575
3 Cross references
208 Possible Orthologues:

60s Ribosomal Protein L22

Ensembl ID : ENSXMAG00000014707
Gene Symbol: LOC102226026
2 Cross references
198 Possible Orthologues:

60s Ribosomal Protein L26

Ensembl ID : ENSXMAG00000010281
Gene Symbol: LOC102219960
3 Cross references
477 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSXMAG00000027567
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSXMAG00000002960
Gene Symbol: ADAM17
3 Cross references
208 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSXMAG00000009810
Gene Symbol: ADAM17
3 Cross references
210 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSXMAG00000020886
Gene Symbol: ADAMTS5
4 Cross references
199 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSXMAG00000028611
Gene Symbol: ADRM1
3 Cross references
191 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSXMAG00000006673
Gene Symbol: AKT1
3 Cross references
195 Possible Orthologues:

Akt Serine/threonine Kinase 2

Ensembl ID : ENSXMAG00000012453
Gene Symbol: AKT2
3 Cross references
210 Possible Orthologues:

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSXMAG00000009140
Gene Symbol: ALK
3 Cross references
193 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).